Global Retinoblastoma Treatment Outcomes: Association with National Income Level.
Por:
Tomar AS, Finger PT, Gallie B, Kivelä TT, Mallipatna A, Zhang C, Zhao J, Wilson MW, Brenna RC, Burges M, Kim J, Khetan V, Ganesan S, Yarovoy A, Yarovaya V, Kotova E, Yousef YA, Nummi K, Ushakova TL, Yugay OV, Polyakov VG, Ramirez-Ortiz MA, Esparza-Aguiar E, Chantada G, Schaiquevich P, Fandino A, Yam JC, Lau WW, Lam CP, Sharwood P, Moorthy S, Long QB, Essuman VA, Renner LA, Semenova E, Català-Mora J, Correa-Llano G, Carreras-Bertran E and American Joint Committee on Cancer Ophthalmic Oncology Task Force
Publicada:
1 may 2021
Ahead of Print:
29 sep 2020
Categoría:
Ophthalmology
Resumen:
PURPOSE: To compare metastasis-related mortality, local treatment failure, and globe salvage after retinoblastoma in countries with different national income levels. DESIGN: International, multicenter, registry-based retrospective case series. PARTICIPANTS: Two thousand one hundred ninety patients, 18 ophthalmic oncology centers, and 13 countries on 6 continents. METHODS: Multicenter registry-based data were pooled from retinoblastoma patients enrolled between January 2001 and December 2013. Adequate data to allow American Joint Committee on Cancer staging, eighth edition, and analysis for the main outcome measures were available for 2085 patients. Each country was classified by national income level, as defined by the 2017 United Nations World Population Prospects, and included high-income countries (HICs), upper middle-income countries (UMICs), and lower middle-income countries (LMICs). Patient survival was estimated with the Kaplan-Meier method. Logistic and Cox proportional hazards regression models were used to determine associations between national income and treatment outcomes. MAIN OUTCOME MEASURES: Metastasis-related mortality and local treatment failure (defined as use of secondary enucleation or external beam radiation therapy). RESULTS: Most (60%) study patients resided in UMICs and LMICs. The global median age at diagnosis was 17.0 months and higher in UMICs (20.0 months) and LMICs (20.0 months) than HICs (14.0 months; P < 0.001). Patients in UMICs and LMICs reported higher rates of disease-specific metastasis-related mortality and local treatment failure. As compared with HICs, metastasis-related mortality was 10.3-fold higher for UMICs and 9.3-fold higher for LMICs, and the risk for local treatment failure was 2.2-fold and 1.6-fold higher, respectively (all P < 0.001). CONCLUSIONS: This international, multicenter, registry-based analysis of retinoblastoma management revealed that lower national income levels were associated with significantly higher rates of metastasis-related mortality, local treatment failure, and lower globe salvage.
Filiaciones:
Tomar AS:
Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York, USA
Finger PT:
Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York, USA
Gallie B:
The Eye Cancer Clinic, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Kivelä TT:
Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Mallipatna A:
Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Canada
Zhang C:
Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China
Zhao J:
Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China
Wilson MW:
Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, Memphis, Tennessee, USA
Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
Brenna RC:
Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, Memphis, Tennessee, USA
Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
Burges M:
Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, Memphis, Tennessee, USA
Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
Kim J:
USC Roski Eye Institute, Keck Medical School of the University of Southern California, Los Angeles, California
The Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA
Khetan V:
Department of Vitreoretina Services, Sankara Nethralaya, Chennai, Tamil Nadu, India
Ganesan S:
Department of Vitreoretina Services, Sankara Nethralaya, Chennai, Tamil Nadu, India
Yarovoy A:
Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation
Yarovaya V:
Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation
Kotova E:
Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation
Yousef YA:
Department of Surgery (Ophthalmology), King Hussein Cancer Center, Amman, Jordan
Nummi K:
Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Ushakova TL:
SRI of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation
Medical Academy of Postgraduate Education, Moscow, Russian Federation
Yugay OV:
SRI of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation
Polyakov VG:
SRI of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation
Medical Academy of Postgraduate Education, Moscow, Russian Federation
Ramirez-Ortiz MA:
Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
Esparza-Aguiar E:
Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
Chantada G:
Precision Medicine Coordination Hospital JP Garrahan, Buenos Aires, Argentina and CONICET, National Scientific and Technical Research Council, Argentina
Schaiquevich P:
Precision Medicine Coordination Hospital JP Garrahan, Buenos Aires, Argentina and CONICET, National Scientific and Technical Research Council, Argentina
Fandino A:
Ophthalmology Service Hospital JP Garrahan, Buenos Aires, Argentina
Yam JC:
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Kowloon, Hong Kong
Lau WW:
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Kowloon, Hong Kong
Lam CP:
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Kowloon, Hong Kong
Sharwood P:
Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, University of Sydney, Australia
Moorthy S:
KK Women's and Children's Hospital, Singapore
Long QB:
KK Women's and Children's Hospital, Singapore
Essuman VA:
Ophthalmology Unit, Department of Surgery, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana
Renner LA:
Department of Child Health, University of Ghana Medical School, Accra, Ghana
Semenova E:
Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York, USA
Català-Mora J:
Retinoblastoma Unit, Department of Ophthalmology, Hospital Sant Joan de Déu. Esplugues de Llobregat. Barcelona, Spain
:
Retinoblastoma Unit, Department of Oncology, Hospital Sant Joan de Déu. Esplugues de Llobregat. Barcelona, Spain
Carreras-Bertran E:
Retinoblastoma Unit, Department of Oncology, Hospital Sant Joan de Déu. Esplugues de Llobregat. Barcelona, Spain
hybrid, Green Published
|